Actively Recruiting
Study to Evaluate Safety and Effects of a Single Subretinal Injection of ASP2020 in People With Stargardt-Type Macular Dystrophies
Led by Astellas Institute for Regenerative Medicine · Updated on 2026-10-28
30
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Macular dystrophies are inherited eye conditions that affect the macula, the central part of the retina responsible for detailed vision. Stargardt disease STGD and STGD-like macular dystrophies cause gradual loss of central vision, usually starting in childhood or adolescence. This early development study evaluates the safety and tolerance of ASP2020, a stem cell treatment designed to replace damaged cells in people with STGD-type macular dystrophies. ASP2020 consists of human stem cells transformed into macular cells and is given as a single injection under the retina via surgery performed under general anesthesia. After the injection, a steroid is administered into the eye to reduce swelling. The study is divided into two parts Part 1 tests low and high doses in adults and teenagers with a 6-month gap between groups to monitor safety, while Part 2 treats adults, teenagers, and children with the optimal dose determined from Part 1. Participants stay in the study for about one year with multiple clinic visits for safety monitoring and various eye exams including imaging and blood tests. Researchers will track adverse events, immune responses, and changes in vision and retinal health using several specific tests to assess the impact of ASP2020 and ensure participant safety throughout the study.
CONDITIONS
Brief Title
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Research Team
A
Astellas Institute for Regenerative Medicine
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here